Clinical Trial Update: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating different doses of BI 1703880 in combination with Ezabenlimab to assess tolerability in adults with advanced solid tumors. Recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BI 1703880
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Solid Tumors | Phase 1 | Status: RECRUITING